Gynecologic Oncology Reports最新文献

{"title":"Racial differences in endometrial cancer genomics and outcomes using UNCseqTM targeted DNA sequencing","authors":"Meredith A. Newton ,&nbsp;Jason D. Merker ,&nbsp;Weida Gong ,&nbsp;Sushant Patil ,&nbsp;Xianming Tan ,&nbsp;David L. Cocoran ,&nbsp;Adam D. Pfefferle ,&nbsp;Michele C. Hayward ,&nbsp;Russell Broaddus ,&nbsp;Hazel B. Nichols ,&nbsp;Andrew F. Olshan ,&nbsp;Bernard Weissman ,&nbsp;Temitope O. Keku ,&nbsp;Victoria Bae-Jump","doi":"10.1016/j.gore.2025.101795","DOIUrl":"10.1016/j.gore.2025.101795","url":null,"abstract":"<div><h3>Objective</h3><div>To use an institution-sponsored targeted sequencing effort to characterize the genomic differences in endometrioid and serous endometrial cancers (ECs) between Black and White patients and to investigate the impact on clinical outcomes.</div></div><div><h3>Methods</h3><div>Tumor tissue from Black and White patients with serous or endometrioid ECs underwent DNA sequencing using the UNCseq^TM panel. Progression-free survival (PFS) and overall survival (OS) were assessed for all patients and within histologic and molecular subcategories using clinicopathologic data from the medical record.</div></div><div><h3>Results</h3><div>Tumor tissue from 200 endometrioid or serous ECs were included, with 169 tumors (84.5 %) from White and 31 (15.5 %) from Black patients. Black patients more frequently had serous (<em>vs</em>. endometrioid, p &lt; 0.0001) and TP53 mutant (by modified TCGA subclassification, p = 0.01) tumors, compared to White patients. Over a median follow-up of 62.4 months, PFS and OS were significantly shorter for Black patients (p &lt; 0.04). Modified TCGA categorized TP53 mutant tumors had the worst PFS and OS (p &lt; 0.04). Of serous tumors, 25.0 % were categorized as POLE, MSI or TP53 wild type, whereas 11.6 % of endometrioid tumors were categorized as TP53 mutant. White patients more often had somatic mutations in <em>ARID1A</em> or <em>PTEN</em> (p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Several potential molecular drivers of the racial disparity in EC were identified. Future studies are warranted to validate the clinical impact of these findings amongst a larger diverse study population and evaluate their potential as clinically actionable targets in treatment.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101795"},"PeriodicalIF":1.2,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma","authors":"Stephanie Cham ,&nbsp;Niya Xiong ,&nbsp;Nabihah Tayob ,&nbsp;Carolyn Krasner ,&nbsp;Alexi A. Wright ,&nbsp;Elizabeth K. Lee ,&nbsp;Hannah Sawyer ,&nbsp;Cara Mathews ,&nbsp;Panagiotis A. Konstantinopoulos ,&nbsp;Ursula A. Matulonis ,&nbsp;Joyce F. Liu","doi":"10.1016/j.gore.2025.101796","DOIUrl":"10.1016/j.gore.2025.101796","url":null,"abstract":"<div><h3>Purpose</h3><div>Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.</div></div><div><h3>Patients and methods</h3><div>This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed <em>TP53</em> alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orally once daily days 1–5 and 8–12 of a 21 day cycle until progression. The co-primary endpoints were objective response rate (ORR) and rate of progression-free survival (PFS) at 6 months. Molecular alterations were identified by targeted next generation sequencing where available.</div></div><div><h3>Results</h3><div>9 patients enrolled prior to drug discontinuation by the sponsor. ORR was 22.2 % (95 % CI 2.8–60 %) with 2 partial responses. 3 patients (33.3 %) had stable disease. Median PFS was 2.7 months (95 % CI 0.9 − not reached). Treatment-related adverse events (all grades) occurred in 8 patients (88.9 %), most commonly diarrhea (77.8 %) and fatigue (66.7 %).</div></div><div><h3>Conclusion</h3><div>In this phase II trial of 9 patients with <em>TP53</em>-mutated UCS, adavosertib demonstrated limited activity. However, future studies of molecular alterations and combinatorial strategies continue to be of interest in UCS with limited treatment options.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101796"},"PeriodicalIF":1.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144501022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-review: Perioperative pain management in gynecologic oncology − strategies and future directions","authors":"Teresa K.L. Boitano ,&nbsp;Benjamin Lai ,&nbsp;Sean C. Dowdy ,&nbsp;J.Michael Straughn","doi":"10.1016/j.gore.2025.101788","DOIUrl":"10.1016/j.gore.2025.101788","url":null,"abstract":"<div><div>This mini-review discusses important factors in opioid use in gynecologic oncology in the perioperative setting. Evidence-based prescribing guidelines, multimodal analgesia strategies, and individualized care in patients with a history of opioid use are discussed. Opioid tapering and its potential risks are also discussed. Additionally, we touch on machine learning in optimizing analgesia. By bridging evidence-based practices and advancements, this review outlines actionable recommendations to maximize patient care and facilitate responsible opioid stewardship in gynecologic<!--> <!-->oncology.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101788"},"PeriodicalIF":1.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144489987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraepithelial lesions of the uterine cervix during pregnancy: reaffirming the safety of conservative management","authors":"Meirovitz Mihai ,&nbsp;Pasternak Maya ,&nbsp;Kessous Roy ,&nbsp;Davidesko Sharon","doi":"10.1016/j.gore.2025.101792","DOIUrl":"10.1016/j.gore.2025.101792","url":null,"abstract":"<div><h3>Objectives</h3><div>Diagnosis of high-grade squamous intraepithelial lesions (HGSIL) during pregnancy is not uncommon, and managing these cases presents clinical challenges. In this study we evaluated the safety and outcomes of conservative management for high-grade squamous intraepithelial lesions (HGSIL) diagnosed during pregnancy.</div></div><div><h3>Methods</h3><div>A retrospective case series was conducted at Soroka University Medical Center (2011–2020) including pregnant women with histologically confirmed HGSIL managed conservatively during pregnancy and treated postpartum.</div></div><div><h3>Results</h3><div>Thirty-two women were included. The mean age at diagnosis was 31.2 ± 3.4 years, with most diagnosed in the first trimester (mean gestational age 8.1 ± 4.1 weeks). The average gestational age at delivery was 39.3 ± 1.0 weeks, and mean birth weight was 3045.6 ± 501.7 g. Postpartum conization showed complete regression in 15.6 %, regression to LGSIL in 6.3 %, and persistent HGSIL in 78.1 %. No cases progressed to invasive cancer. During 5.7 ± 2.9 years of follow-up, three patients (9.4%) experienced recurrence requiring repeat conization.</div></div><div><h3>Conclusions</h3><div>Conservative management of HGSIL during pregnancy appears to be a safe and effective approach. In our case series, no progression to malignancy was observed, and postpartum outcomes were favourable. Deferring excisional treatment until after delivery is supported by these findings<strong>.</strong></div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101792"},"PeriodicalIF":1.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144481484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer","authors":"Michael Danziger ,&nbsp;Samuel Singer ,&nbsp;Joan Tymon-Rosario","doi":"10.1016/j.gore.2025.101791","DOIUrl":"10.1016/j.gore.2025.101791","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have transformed the management of advanced and recurrent endometrial carcinoma (EC). ICI therapy can be associated with complex, multisystemic immune-related adverse events (irAEs), which present new challenges in gynecologic oncologic care management. Anti-Yo-positive paraneoplastic cerebellar ataxia (PCA) is a rare syndrome that can be associated with gynecologic malignancies that presents with subacute gait ataxia with imbalance and falls and can demonstrate cerebellar atrophy on imaging.</div></div><div><h3>Case</h3><div>Here we describe a patient with stage IVB uterine carcinosarcoma who developed subacute progressive gait ataxia with falls while on maintenance dostarlimab. Neurological workup revealed the presence of anti-Yo antibodies, suggesting a paraneoplastic neurological syndrome (PNS), specifically paraneoplastic cerebellar degeneration (PCD). Dostarlimab was omitted from her subsequent course of treatment, and immunosuppression started with initial improvement followed by stabilization of symptoms.</div></div><div><h3>Conclusion</h3><div>This case demonstrates the protean nature and sometimes subtle onset of toxicities associated with these agents, requiring complex coordination of care and multidisciplinary management, particularly as these agents become increasingly important in the management of gynecologic malignancies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101791"},"PeriodicalIF":1.2,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma","authors":"Julia Chalif ,&nbsp;Molly Morton ,&nbsp;Eric McLaughlin ,&nbsp;Anna Gonzalez ,&nbsp;Jessica Fulton ,&nbsp;Jessica Sciuva ,&nbsp;Ioana Marcu ,&nbsp;Kristin L. Bixel ,&nbsp;David E. Cohn ,&nbsp;Casey M. Cosgrove ,&nbsp;Larry J. Copeland ,&nbsp;Christa I. Nagel ,&nbsp;Floor Backes ,&nbsp;David M. O’Malley ,&nbsp;Daniel J. Spakowicz ,&nbsp;Laura M. Chambers","doi":"10.1016/j.gore.2025.101782","DOIUrl":"10.1016/j.gore.2025.101782","url":null,"abstract":"<div><h3>Objective</h3><div><strong>(s):</strong> To assess the effect of medication use during immune checkpoint inhibitor (ICI) therapy on treatment response and oncologic outcomes.</div></div><div><h3>Methods</h3><div>An IRB-approved single-institution retrospective cohort study was performed in patients with endometrial cancer (EC) and cervical cancer (CC) who were treated with ICIs from January 1, 2017 to January 1, 2023. Concomitant medications used during the ICI course were recorded. The associations between medication use and ICI response, progression-free survival (PFS), and overall survival (OS) was assessed.</div></div><div><h3>Results</h3><div>217 CC and EC patients were treated with ICIs during this study period; 32 % (n = 71) had CC, and 67 % (n = 146) had EC. There was a significant difference in ICI complete response between CC patients who did and did not use oral steroids during treatment. Of CC patients who achieved a complete response, 28 % (n = 7) used steroids vs. 13.6 % (n = 6) of non-steroid users (Fisher’s exact p = 0.045). In patients with EC, proton pump inhibitor (PPI) use was associated with ICI response, with 43.8 % (n = 21) of PPI users achieving a complete response vs. 16.3 % (n = 15) of non-PPI users (chi-squared p = 0.002). PPI use in the EC cohort was associated with improved progression-free survival and overall survival (log-rank p &lt; 0.05). This was also demonstrated among mismatch repair-deficient EC patients where PPI use during ICI therapy significantly associated with both PFS (HR 0.26, 95 % CI 0.12–0.55; p &lt; 0.001) and OS (HR 0.22, 95 % CI 0.08–0.59; p &lt; 0.001).</div><div>Conclusion(s)</div><div>In this retrospective cohort study of EC and CC patients treated with ICI therapy, medication use, specifically PPIs and oral steroids, was seen to have a significant positive effect on ICI response, PFS, and OS.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101782"},"PeriodicalIF":1.2,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144481483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel Decisions: Current Evidence and Best Practices for Lymph Node Assessment in Vulvar and Cervical Cancers","authors":"Malavika Perinchery ,&nbsp;Kathryn Mills","doi":"10.1016/j.gore.2025.101786","DOIUrl":"10.1016/j.gore.2025.101786","url":null,"abstract":"<div><div>Sentinel lymph node dissection (SLND) and biopsy has revolutionized the world of surgical oncology. SLND offers benefits such as decreased risk of lower extremity edema, lower infection rates and reduced blood loss. Many studies have explored the application of SLNB in the context of vulvar and cervical cancers. Evidence has demonstrated that it is a reasonable alternative to complete lymphadenectomy in the appropriate candidate. Furthermore, utilization of different dyes, such as ICG, has resulted in positive outcomes, resulting in shifts in practice. This review explores the current data and best practices for sentinel lymph node mapping and dissection in vulvar and cervical cancers.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101786"},"PeriodicalIF":1.2,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144471080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of a squamous cell carcinoma arising in a vulvar cutaneous horn","authors":"Michael Bell ,&nbsp;Erin Crane ,&nbsp;Robert Tucker Burks","doi":"10.1016/j.gore.2025.101784","DOIUrl":"10.1016/j.gore.2025.101784","url":null,"abstract":"<div><h3>Background</h3><div>Cutaneous horns are rare lesions that consist of a proliferation of keratotic material, often representing animal horns. Rarely, they may be associated with underlying squamous cell carcinomas. Here, we present a case report of a cutaneous horn arising in a squamous cell carcinoma of the vulva.</div></div><div><h3>Objective</h3><div>In this report, we highlight the case of an 84 year-old patient who presented with a vulvar cutaneous horn. After resection, pathology demonstrated an invasive squamous cell carcinoma of the vulva. We provide a review of available literature and describe a rare manifestation of a squamous cell carcinoma of the vulva. Given her frailty, no further treatment was pursued, and she remains in observation without evidence of recurrence.</div></div><div><h3>Conclusions</h3><div>Our case highlights a rare presentation of a vulvar cutaneous horn arising within invasive squamous cell carcinoma of the vulva. While most cutaneous horns are benign, a subset may harbor malignancy, and therefore excision is warranted. Additional treatment is dependent upon histopathology, disease site, and patient factors.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101784"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144471079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of cervical extrarenal Wilms tumor: diagnostic challenges and fertility-sparing management","authors":"Cansu Turker Saricoban ,&nbsp;Ayse Yavuz ,&nbsp;Yagmur Arslan ,&nbsp;Ozge Gokbasi ,&nbsp;Abdullah Serdar Acikgoz ,&nbsp;Tevfik Tugan Bese ,&nbsp;Sennur Ilvan","doi":"10.1016/j.gore.2025.101787","DOIUrl":"10.1016/j.gore.2025.101787","url":null,"abstract":"<div><h3>Objectives</h3><div>Extrarenal Wilms tumor (ERWT) is an exceedingly rare neoplasm, particularly when located in the uterine cervix.</div></div><div><h3>Methods</h3><div>We report the case of a 26-year-old nulliparous female who presented with a large cervical mass and underwent clinical, radiological, and pathological evaluation.</div></div><div><h3>Results</h3><div>Initial biopsy revealed biphasic morphology with atypical epithelial and stromal components, while the absence of a blastemal component posed a diagnostic challenge. Subsequent excision demonstrated classic triphasic morphology, confirming the diagnosis of ERWT. The patient underwent fertility-preserving surgery followed by adjuvant chemotherapy and remains disease-free at one-year follow-up.</div></div><div><h3>Conclusions</h3><div>This case highlights the importance of considering ERWT in the differential diagnosis of cervical tumors and demonstrates that standard renal Wilms tumor treatment protocols can be effectively adapted to extrarenal locations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101787"},"PeriodicalIF":1.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review","authors":"Chenge Zhang ,&nbsp;Miao Dai ,&nbsp;Jun Yang ,&nbsp;Wenfang Tian ,&nbsp;Si Huang ,&nbsp;Feng Bi ,&nbsp;Kai Zheng ,&nbsp;Jie Tang","doi":"10.1016/j.gore.2025.101785","DOIUrl":"10.1016/j.gore.2025.101785","url":null,"abstract":"<div><h3>Objectives</h3><div>For advanced ovarian cancer (OC), particularly OC with HR-deficient, surgery combined with adjuvant chemotherapy and maintenance therapy with PARPi/bevacizumab is the standard effective first-line treatment regimen. However, the clinical<!--> <!-->benefit<!--> <!-->of therapy for<!--> <!-->HR-proficient advanced OC is<!--> <!-->limited, with no significant increase in the 5-year survival rate.</div></div><div><h3>Methods</h3><div>In this case study, a patient with Stage IVB OC, who tested HR-proficient, but PD-L1 positive, experienced significant tumor shrinkage (&gt;90 %) after undergoing 3 cycles of neoadjuvant chemotherapy using TC (Paclitaxel with Carboplatin) with Cadonilimab (a PD-1/CTLA-4 bispecific antibody) therapy.</div></div><div><h3>Results</h3><div>This resulted in an R0 resection during intermittent debulking surgery. After surgery, while the patient received standard first-line chemotherapy with TC + bevacizumab, the CA125 level failed to normalize. Nonetheless, upon readministration of Cadonilimab, CA125 levels normalized and have been maintained to date. The patient has remained free of recurrence and metastasis for more than 23 months after neoadjuvant therapy, before the data cutoff date, March 10, 2025.</div></div><div><h3>Conclusions</h3><div>This case illustrates that individuals suffering from advanced OC, particularly those with HR-proficient and PD-L1 positive status, may benefit from first-line treatment with Cadonilimab. Identifying the population that may benefit from immune therapy is crucial. The novel PD-1/CTLA-4 bispecific antibody merits further attention for managing advanced epithelial ovarian cancer.</div><div><strong>Trial registration:</strong> NCT05430906, registration date: June 20,2022.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101785"},"PeriodicalIF":1.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}